<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In both <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> and <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo>, <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) secondary prevention basically relies on the histology detection of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>In <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel diseases</z:e> (IBD) setting, <z:mpath ids='MPATH_589'>dysplasia</z:mpath> identifies the subgroup of patients eligible to a (more) strict surveillance program (or prophylactic colectomy) </plain></SENT>
<SENT sid="2" pm="."><plain>In the clinical practice, a number of issues might affect the benefit of the clinico-pathological surveillance of the IBD-<z:mpath ids='MPATH_589'>dysplasia</z:mpath>-patients: sampling errors, inconsistency in biopsy assessment, patients' drop-out, etc </plain></SENT>
<SENT sid="3" pm="."><plain>Even in such a multifaceted context, evidence has been provided that surveillance of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> is effective in reducing both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> mortality and morbidity </plain></SENT>
<SENT sid="4" pm="."><plain>This manuscript focuses on current issues concerning the histology assessment of the IBD-associated dysplastic lesions </plain></SENT>
</text></document>